NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma
- Conditions
- Colorectal AdenomaColorectal Carcinoma
- Interventions
- Procedure: Biospecimen CollectionOther: Questionnaire AdministrationOther: Placebo AdministrationProcedure: Rectal Biopsy
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 81
- Registration Number
- NCT02965703
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
- Conditions
- Recurrent MelanomaStage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7Unresectable MelanomaAdvanced MelanomaStage III Cutaneous Melanoma AJCC v7Stage IIIA Cutaneous Melanoma AJCC v7
- Interventions
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 43
- Registration Number
- NCT02965716
- Locations
- 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸CTCA at Western Regional Medical Center, Goodyear, Arizona, United States
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
- Conditions
- Familial Adenomatous PolyposisAttenuated Familial Adenomatous Polyposis
- Interventions
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 46
- Registration Number
- NCT02961374
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇵🇷University of Puerto Rico, San Juan, Puerto Rico
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes
- First Posted Date
- 2016-11-10
- Last Posted Date
- 2023-08-01
- Target Recruit Count
- 24
- Registration Number
- NCT02960659
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
- Conditions
- Stage III Breast Cancer AJCC v7Invasive Breast CarcinomaStage 0 Breast Cancer AJCC v6 and v7Stage II Breast Cancer AJCC v6 and v7Stage I Breast Cancer AJCC v7Triple-Negative Breast Carcinoma
- Interventions
- Procedure: Biospecimen CollectionOther: Laboratory Biomarker AnalysisOther: Patient ObservationOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Radiation Therapy
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1155
- Registration Number
- NCT02954874
- Locations
- 🇺🇸
Henry Ford Medical Center-Columbus, Novi, Michigan, United States
🇺🇸Henry Ford Warren Hospital - GLCMS, Warren, Michigan, United States
🇺🇸United Hospital, Saint Paul, Minnesota, United States
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
- Conditions
- Primary Peritoneal CancerFallopian Tube CancerOvarian Cancer
- Interventions
- Biological: Autologous Monocytes + ACTIMMUNE + SYLATRON
- First Posted Date
- 2016-10-28
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 18
- Registration Number
- NCT02948426
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
- Conditions
- GlioblastomaAstrogliomaGliosarcomaBrain TumorAstrocytoma
- Interventions
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT02942264
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Food Intake Response to Short-Term Modifications of Metabolism in Humans
- Conditions
- Healthy Volunteers
- First Posted Date
- 2016-10-20
- Last Posted Date
- 2025-01-15
- Target Recruit Count
- 54
- Registration Number
- NCT02939404
- Locations
- 🇺🇸
NIDDK, Phoenix, Phoenix, Arizona, United States
Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents
- Conditions
- Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT02936752
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸University of Kansas Clinical Research Center, Fairway, Kansas, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2016-10-14
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT02933255
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States